Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

SPR Detection System

By Drug Discovery Trends Editor | March 5, 2009

FUJIFILM AP-3000FUJIFILM Corporation launched the AP-3000 label-free surface plasmon resonance (SPR) detection system for fragment-based lead discovery (FBLD). The AP-3000 is a high-sensitivity SPR biosensor that can detect small fragments with weak binding affinities accurately, reliably, and reproducibly with high throughput, according to FUJIFILM Corporation.
 
The AP-3000 is capable of the simultaneous measurement of multiple samples (up to six samples), enabling label-free screening of 3,840 samples per day. The system is designed to run all steps of the SPR process unattended.
 
The system optimizes the injection, flow, and measurement of low volume samples, and reduces the amount of protein and compound needed for analysis. The plastic biosensor can be used up to 400 times, thereby reducing running costs.
 
Some of the benefits of the system are: high sensitivity, the system can measure the binding level of small molecules as low as 100 Daltons; high throughput, the binding level of 3,840 analytes can be obtained in 24 hours; automatic process, all processes of preparing the materials, immobilizing proteins, injecting compounds, and obtaining binding data are fully automated; and low sample and running costs, technology to inject and circulate small amounts of samples lowers the amount of proteins and compounds being used while plastic biosensors can be used up to 400 times each, reducing running costs, according to the company.

 https://lifescience.fujifilm.com.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50